Covid-19 (Temas de Saúde Pública)
Delta “plus”: cientistas dizem que é cedo demais para afirmar o risco dessa variante da Covid-19.
28 Jun, 2021 | 10:41hDelta plus India: Scientists say too early to tell risk of Covid-19 variant – BBC
Perspectiva | Uma dose de vacina é suficiente para quem já teve COVID? O que diz a ciência.
28 Jun, 2021 | 10:40hIs one vaccine dose enough if you’ve had COVID? What the science says – Nature
Relacionado: Another study shows a single dose of an mRNA vaccine has maximal effects in those with past infection.
Comentário no Twitter
One vaccine dose for prior covid: @ElieDolgin reviews the recent data @Nature https://t.co/amJ4RcGtuW
Vaccination cards/proof should be modified here to equate prior covid as the 1st dose and not force people to get an unnecessary 2nd dose— Eric Topol (@EricTopol) June 27, 2021
“Long Covid”: estudo mostra que metade dos adultos jovens com COVID-19 apresentaram sintomas 6 meses depois da doença.
25 Jun, 2021 | 10:45hEstudo original: Long COVID in a prospective cohort of home-isolated patients – Nature Medicine
Comentário no Twitter
Analysis of a prospectively enrolled cohort of patients with #SARSCoV2 infections reveals a high proportion who experienced #LongCovid symptoms at 6 months, despite being relatively young and having only mild to moderate acute #COVID19 symptoms https://t.co/fuW2QpfJog
— Nature Medicine (@NatureMedicine) June 23, 2021
[Preprint] “Long Covid”: 1/3 das pessoas infectadas apresentou sintomas de longa duração.
25 Jun, 2021 | 10:44hCovid-19: Third of people infected have long term symptoms – The BMJ
Estudo original (preprint): Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people – Imperial College London
Grupo do CDC afirma que ainda não há evidência sugerindo a necessidade de reforço da vacina contra Covid.
25 Jun, 2021 | 10:43hNo evidence yet to suggest Covid vaccine booster is needed, CDC group says – NBC News
Opinião relacionada: 7 Reasons Why We Should Not Need Boosters for COVID-19 – by Monica Ghandi, MD
Perspectiva | As vacinas chinesas contra COVID têm desempenho inferior? A escassez de estudos de vida real deixa questões sem respostas.
25 Jun, 2021 | 10:42hRelacionados: WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic. E Brazilian town experiment shows mass vaccination can wipe out COVID-19.
Opinião | As vacinas de mRNA são extraordinárias, mas a Novavax é ainda melhor.
25 Jun, 2021 | 10:41hThe mRNA Vaccines Are Extraordinary, but Novavax Is Even Better – The Atlantic
Comentário no Twitter
The tale of mRNA vaxes & new technology hype, & underestimating the importance of Novavax – a more old-school vaccine with efficacy just as high, & lower adverse events. My latest in @TheAtlantic https://t.co/Hid29G5mkC
— Hilda Bastian, PhD (@hildabast) June 24, 2021
Variante Delta da COVID impulsiona picos globais e complica as reaberturas.
25 Jun, 2021 | 10:39hDelta COVID variant fuels global surges, complicates reopenings – CIDRAP
Mais um estudo mostra que uma dose única de vacina de mRNA tem efeito máximo em pacientes com infecção prévia.
24 Jun, 2021 | 11:07hPrimary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses – ACS Nano
Relacionado: France recommends single dose of vaccine if previous Covid infection detected. E [Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19. E Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19
Comentário no Twitter
Prior covid? Unless it's a severe case, one-dose mRNA vaccine adds considerable protection and nothing added by 2nd dose. This is now concordant w/ >20 studieshttps://t.co/8Qpuw193zk @acsnano pic.twitter.com/TJNbl8HPy9
— Eric Topol (@EricTopol) June 23, 2021
Relatório | Variantes do SARS-CoV-2 e vacinas.
24 Jun, 2021 | 11:06hSARS-CoV-2 Variants and Vaccines – New England Journal of Medicine